Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 143,706 Shares of Stock

Posted by Ethan Ryder on Nov 4th, 2026

Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 143,706 shares of the business’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $30.38, for a total transaction of $4,365,788.28. Following the transaction, the insider owned 161,679 shares in the company, valued at $4,911,808.02. The trade was a 47.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

On Monday, November 2nd, Corporate Gp Vi Ltd. Qiming sold 43,930 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.84, for a total transaction of $1,310,871.20.
On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The stock was sold at an average price of $32.77, for a total transaction of $3,304,428.49.
On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The shares were sold at an average price of $31.39, for a total transaction of $2,664,822.66.
On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total transaction of $4,044,632.48.
On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.59, for a total transaction of $4,525,301.06.
On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total transaction of $3,924,676.63.
On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total transaction of $6,329,182.65.
On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The shares were sold at an average price of $26.34, for a total value of $1,988,880.72.
On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total value of $3,674.72.

Alamar Biosciences Stock Up 4.4%

Shares of Alamar Biosciences stock opened at $30.22 on Wednesday. The company has a 50-day moving average price of $30.49. Alamar Biosciences, Inc. has a one year low of $18.84 and a one year high of $39.61. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.85 and a quick ratio of 10.23.

Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.03. The firm had revenue of $33.55 million during the quarter. Research analysts anticipate that Alamar Biosciences, Inc. will post -1.22 EPS for the current year.

Alamar Biosciences News Roundup

Here are the key news stories impacting Alamar Biosciences this week:

Positive Sentiment: For Q3 2026, Alamar reported a loss of $0.19 per share, beating the $0.22-per-share loss consensus, and revenue of $33.55 million. The company also raised its 2026 revenue guidance, a potentially supportive signal for its growth outlook. Alamar reports Q3 results and raises 2026 revenue guidance
Positive Sentiment: Alamar announced a scientific collaboration with GSK using its NULISA platform in a large-scale study of protein signatures across several disease areas. The partnership could raise the platform’s profile, though no financial terms were disclosed. Alamar partners with GSK on proteomic study
Positive Sentiment: Alamar and Nightingale Health will lead an 80,000-sample UK Biobank study focused on neurodegenerative diseases, with support from major research organizations. The project may showcase Alamar’s technology in a significant research effort; direct commercial impact was not specified. Alamar and Nightingale to lead UK Biobank study
Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming disclosed sales totaling 187,636 shares across October 30 and November 2. Large-holder selling can weigh on sentiment, although the filings do not state the reason for the sales. SEC filing on shareholder transactions

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ALMR shares. Stifel Nicolaus increased their target price on Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. boosted their price target on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. TD Cowen restated a “buy” rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. Finally, Weiss Ratings lowered shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 23rd. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $31.80.

Get Our Latest Analysis on ALMR

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ALMR. China Universal Asset Management Co. Ltd. bought a new stake in Alamar Biosciences during the third quarter worth $196,000. Squarepoint Ops LLC purchased a new stake in Alamar Biosciences in the 2nd quarter valued at $283,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in Alamar Biosciences by 18.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after acquiring an additional 10,461 shares in the last quarter. State Street Corp bought a new position in Alamar Biosciences during the 2nd quarter valued at $3,930,000. Finally, Wellington Management Group LLP bought a new position in Alamar Biosciences during the 2nd quarter valued at $12,407,000.

About Alamar Biosciences

(Get Free Report)

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.